RDHL

Nov 02, 7:36 AMRedHill Biopharma reports Crohn’s candidate RHB-204 kills MAP bacteria in vitro with potency comparable to prior RHB-104

Peers: IRWD AYTU CPIX SCYX BFRI TLPH TXMD KMDA APUS SBFM

Scroll to Statements

Index	-
Market Cap	3.65M
Enterprise Value	-0.44M
Income	-
Sales	-
Book/sh	-0.18
Cash/sh	0.58
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	13
IPO	Jan 07, 2013

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	0.71
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.34
Current Ratio	0.34
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	95.56% 86.32%
Sales past 3/5Y	-83.27% -66.14%
EPS Y/Y TTM	94.65%
Sales Y/Y TTM	-
EPS Q/Q	102.33%
Sales Q/Q	-90.20%
Earnings	Apr 27 BMO
EPS/Sales Surpr.	- -

Insider Own	11.09%
Insider Trans	-96.65%
Inst Own	3.48%
Inst Trans	0.32%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-11.84%
SMA50	-24.77%
SMA200	-48.56%
Trades

Shs Outstand	8.89M
Shs Float	7.90M
Short Float	1.62%
Short Ratio	0.06
Short Interest	0.13M
52W High	1.60 -74.37%
52W Low	0.38 7.89%
Volatility	11.65% 11.90%
ATR (14)	0.05
RSI (14)	39.97
Beta	4.86
Rel Volume	0.02
Avg Volume	2.05M
Volume	32,605

Perf Week	-4.18%
Perf Month	-15.27%
Perf Quarter	-29.41%
Perf Half Y	-59.79%
Perf YTD	-60.18%
Perf Year	-62.03%
Perf 3Y	-95.58%
Perf 5Y	-99.99%
Perf 10Y	-100.00%
Recom	-
Target Price	7.75
Prev Close	0.42
Price	0.41
Change %	-1.39%

Avg. Price Target

$7.75

Implied Upside

+1,789.8%

Analysts9incl. previous ratings

Rating Distribution9 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 31, 2021	Initiated	CCantor Fitzgerald	Overweight	$22	+5,264.5%
May 18, 2021	Initiated	HH.C. Wainwright	Buy	$23	+5,508.4%
Sep 11, 2020	Initiated	BBTIG Research	Buy
Jul 12, 2019	Upgrade	WWBB Securities	Buy → Strong Buy
Mar 12, 2019	Upgrade	WWBB Securities	Speculative Buy → Buy
Jan 26, 2018	Initiated	NNomura	Buy	$18	+4,289.2%
Oct 06, 2017	Initiated	SSeaport Global Securities	Buy	$19	+4,533.0%
Oct 04, 2017	Reiterated	HH.C. Wainwright	Buy	$33 → $36	+8,678.3%
Feb 24, 2017	Reiterated	FFBR & Co.	Outperform	$36 → $25	+5,996.1%
Jul 27, 2016	Reiterated	FFBR Capital	Outperform	$33 → $36	+8,678.3%
Sep 29, 2015	Initiated	NNomura	Buy
Jul 29, 2015	Reiterated	RROTH Capital	Buy	$30 → $31	+7,459.1%
Jun 17, 2015	Reiterated	HH.C. Wainwright	Buy	$23 → $32	+7,703.0%
Jun 15, 2015	Reiterated	RROTH Capital	Buy	$27.50 → $30	+7,215.3%

Nov-02-26 07:00AM	Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate (PR Newswire) +13.87%
Oct-19-26 08:00AM	$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma (PR Newswire)
Oct-01-26 03:12PM	Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet (PR Newswire)
Sep-30-26 04:05PM	RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results (PR Newswire)
Sep-01-26 07:01AM	RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota and Clenpiq (FinanceWire)
07:00AM	Loading…
Aug-31-26 07:00AM	RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities (PR Newswire) +36.16%
Jul-28-26 07:00AM	Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development (PR Newswire)
Jun-22-26 04:10PM	RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement (PR Newswire) +10.24%
Jun-18-26 08:00AM	RedHill Biopharma Announces Up To $19.4 Million Private Placement (PR Newswire)
Jun-09-26 07:00AM	RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation (PR Newswire) -21.56%
Jun-08-26 07:00AM	RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo (PR Newswire)
Jun-03-26 12:04PM	RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak (PR Newswire)
Jun-02-26 08:00AM	RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms (PR Newswire)
Apr-30-26 07:00AM	RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease (PR Newswire)
Apr-27-26 08:00AM	RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights (PR Newswire)
08:00AM	Loading…
Apr-22-26 08:00AM	RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 (PR Newswire) +5.82%
Feb-25-26 07:00AM	Joint U.S. Commercialization of RedHill's Talicia Commences (PR Newswire)
Jan-05-26 07:00AM	RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects (PR Newswire) +35.92%
Dec-15-25 07:00AM	RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells (PR Newswire)
Dec-01-25 07:00AM	RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement (PR Newswire)
Nov-04-25 09:30AM	RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement (PR Newswire) -14.96%
Oct-22-25 04:50PM	RedHill Biopharma Receives Nasdaq Staff Determination Notification (PR Newswire)
Oct-20-25 09:05AM	CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO (PR Newswire) +15.33%
09:00AM	RedHill's Talicia Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal (PR Newswire)
Oct-06-25 08:00AM	RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia (PR Newswire)
Sep-29-25 07:00AM	RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo (PR Newswire) +27.17%
Sep-05-25 07:00AM	RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights (PR Newswire) +16.54%
Aug-20-25 09:00AM	RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win (PR Newswire) -7.59%
Aug-18-25 09:00AM	RedHill Received Talicia Licensing Payments Totaling $1.1 Million (PR Newswire) +5.88%
Jul-21-25 09:00AM	RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease (PR Newswire) +26.34%
12:00PM	Loading…
Jul-01-25 12:00PM	RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer (PR Newswire)
May-13-25 07:00AM	RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win (PR Newswire) -5.50%
May-02-25 07:00AM	RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress (PR Newswire)
Apr-28-25 07:03AM	RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107 (PR Newswire) -9.96%
Apr-17-25 04:01PM	RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency (PR Newswire) +9.18%
Apr-16-25 07:00AM	RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption (PR Newswire)
Apr-10-25 07:48AM	RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights (PR Newswire)
Mar-18-25 07:00AM	RedHill Biopharma to Submit FDA-Approved Talicia for UK Marketing Authorisation (PR Newswire)
Mar-12-25 07:00AM	RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results (PR Newswire)
Feb-27-25 07:00AM	RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum (PR Newswire) -6.49%
Feb-26-25 10:36AM	RedHill and Hyloris sign agreement for Bekindas development (Pharmaceutical Technology) -9.41%
Feb-25-25 07:00AM	RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties (PR Newswire) -11.83%
Feb-05-25 06:45AM	RedHill Biopharma launches trial of combination therapy for prostate cancer (Clinical Trials Arena)
Feb-04-25 07:00AM	RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer (PR Newswire)
Jan-21-25 07:00AM	RedHill's Talicia Adds 8 Million Lives With Coverage by Humana's Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published (PR Newswire) +12.30%
Dec-10-24 07:00AM	Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development (PR Newswire) +8.77%
Dec-03-24 07:18AM	RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court (TipRanks) -5.74%
Dec-02-24 07:00AM	RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court (PR Newswire)
Nov-04-24 07:30AM	Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors (PR Newswire)
Oct-28-24 07:00AM	RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND (PR Newswire)
Oct-23-24 07:29AM	RedHill Biopharma and Duke Collaborate on Opaganib Development (TipRanks)
Oct-22-24 07:00AM	RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury (PR Newswire)
Oct-14-24 07:00AM	RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment (PR Newswire)
Oct-01-24 07:27AM	RedHill Biopharma Secures Opaganib COVID-19 Patent (TipRanks) -5.04%
07:00AM	RedHill and Medi-Cal Deal Maintains Talicia Reimbursement Without Prior Authorization for 15 Million Californians (PR Newswire)
Sep-30-24 07:00AM	RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041 (PR Newswire)
Sep-09-24 07:00AM	RedHill's Talicia Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines (PR Newswire) +9.81%
Sep-05-24 07:00AM	RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Sep-03-24 07:00AM	New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality (PR Newswire)
Aug-29-24 07:00AM	RedHill Biopharma Announces First Half 2024 Business Highlights (PR Newswire)
Aug-26-24 07:00AM	RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma (PR Newswire) -6.54%
Aug-21-24 07:00AM	Talicia Launched in the United Arab Emirates (PR Newswire) +25.06%
Aug-19-24 07:56AM	Upcoming Stock Splits This Week (August 19 to August 23) Stay Invested (TipRanks) +10.69%
07:00AM	RedHill Announces Positive Obesity and Diabetes Results with Opaganib (PR Newswire)
Aug-16-24 07:00AM	RedHill Biopharma Announces Plan to Implement ADS Ratio Change (PR Newswire) -22.64%
Aug-01-24 07:00AM	Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease (PR Newswire) +97.87%
Jul-22-24 07:00AM	RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia Lien (PR Newswire) +5.09%
Jul-09-24 08:00AM	RedHill Biopharma Terminates License Agreement for Aemcolo (PR Newswire)
Jun-03-24 07:00AM	RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 (PR Newswire)
May-06-24 07:43AM	Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib (MT Newswires)
07:00AM	RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 (PR Newswire)
Apr-24-24 07:00AM	RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study (PR Newswire)
Apr-08-24 09:23AM	RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights (PR Newswire)
Apr-02-24 07:00AM	RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price (PR Newswire)
Mar-11-24 07:00AM	RedHill Announces New USPTO Patent Covering Talicia Through 2034 (PR Newswire)
Mar-05-24 07:00AM	RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs (PR Newswire) -7.48%
Feb-20-24 07:00AM	RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication (PR Newswire)
Jan-26-24 12:46PM	RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering (PR Newswire)
Jan-25-24 09:05AM	RedHill Biopharma Announces $8 Million Registered Direct Offering (PR Newswire) -39.85%
06:00AM	RedHill Announces New USPTO Patent Grant for Talicia for H. pylori Treatment Through 2042 (PR Newswire)
Dec-20-23 08:45AM	RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola (PR Newswire) +6.06%
Dec-12-23 07:00AM	RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Dec-04-23 07:00AM	RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study (PR Newswire) +13.86%
Dec-03-23 01:11PM	5 Most Volatile Stocks Under $5 For Day Trading (Insider Monkey)
Nov-30-23 09:08AM	Why Is Redhill Biopharma (RDHL) Stock Down 27% Today? (InvestorPlace) -30.56%
Nov-27-23 01:41PM	5 Investors Betting Big on RedHill Biopharma (RDHL) Stock (InvestorPlace) +216.96%
07:00AM	RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia with IP Protection Running to 2034 (PR Newswire)
Nov-14-23 08:00AM	RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market (PR Newswire) +9.00%
Oct-03-23 07:00AM	RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study (PR Newswire) -14.86%
Sep-22-23 04:15PM	RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (PR Newswire) -11.11%
Sep-18-23 07:00AM	RedHill Announces FDA sNDA Approval for Talicia® (PR Newswire)
Sep-05-23 07:00AM	RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®) (PR Newswire)
Aug-17-23 07:00AM	RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights (PR Newswire) +13.41%
Aug-01-23 07:00AM	RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. (PR Newswire)
Jul-31-23 07:00AM	RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA (PR Newswire)
Jul-25-23 03:58PM	RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise (PR Newswire)
Jul-21-23 09:33AM	RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds (PR Newswire) -25.95%
07:00AM	RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development (PR Newswire)
Jun-12-23 08:00AM	RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights (PR Newswire)
May-22-23 07:00AM	RedHill Provides R&D Update (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	#Shares	Value ($)	#Shares Total	SEC Form 4
Raday Gilead	Chief Operating Officer	Oct 01 '26	Sale	14,310,000	1,431	176,910,000	Oct 06 07:00 AM
Raday Gilead	Chief Operating Officer	Jul 10 '26	Sale	14,130,000	1,413	218,780,000	Jul 13 04:03 PM
Raday Gilead	Chief Operating Officer	Apr 06 '26	Sale	15,740,000	1,574	261,060,000	Apr 22 06:09 PM

RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Co-FounderMr. Dror Ben-Asher

Chief Financial OfficerMr. Razi Ingber

MScMr. Gilead Raday MPhil

Chief Corporate & Business Development OfficerMr. Adi Frish

Chief Commercial Officer & DirectorMr. Rick D. Scruggs

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Redhill Biopharma Ltd ADR

Upgrade your Finviz experience